Skip to main content
. 2022 Jul 9;18(1):135–142. doi: 10.1177/19322968221109841

Figure 2.

Figure 2.

Cost-effectiveness acceptability curves for using the Freestyle Libre in different subgroups with diabetes type 1.

Subgroup 1: frequent hypoglycemic events; subgroup 2: high HbA1c; subgroup 3: critical occupation; subgroup 4: multiple indications.